KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

BeOne Medicines (ONC) EBITDA: 2014-2024

Historic EBITDA for BeOne Medicines (ONC) over the last 11 years, with Dec 2024 value amounting to -$568.2 million.

  • BeOne Medicines' EBITDA rose 235.63% to $163.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $182.7 million, marking a year-over-year increase of 120.94%. This contributed to the annual value of -$568.2 million for FY2024, which is 52.95% up from last year.
  • As of FY2024, BeOne Medicines' EBITDA stood at -$568.2 million, which was up 52.95% from -$1.2 billion recorded in FY2023.
  • BeOne Medicines' EBITDA's 5-year high stood at -$568.2 million during FY2024, with a 5-year trough of -$1.8 billion in FY2022.
  • Over the past 3 years, BeOne Medicines' median EBITDA value was -$1.2 billion (recorded in 2023), while the average stood at -$1.2 billion.
  • In the last 5 years, BeOne Medicines' EBITDA spiked by 59.19% in 2021 and then slumped by 164.57% in 2022.
  • BeOne Medicines' EBITDA (Yearly) stood at -$1.7 billion in 2020, then skyrocketed by 59.19% to -$676.4 million in 2021, then crashed by 164.57% to -$1.8 billion in 2022, then skyrocketed by 32.52% to -$1.2 billion in 2023, then surged by 52.95% to -$568.2 million in 2024.